Emerging new therapies for cutaneous T-cell lymphoma

Dermatologic Clinics

Volumn 18, Issue 1, 2000, Pages 147-156

  Duvic, Madeleine ^b   Cather, Jennifer C ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ABT 281; ALITRETINOIN; ASCOMYCIN; ATORVASTATIN; BEXAROTENE; CARMUSTINE; CHLORMETHINE; CORTICOSTEROID; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DIPHTHERIA TOXIN; ETRETIN; ETRETINATE; FENOFIBRATE; FLUDARABINE; GAMMA INTERFERON; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; ISOTRETINOIN; PELDESINE; PENTOSTATIN; PSORALEN; RECOMBINANT INTERLEUKIN 2; RETINOIC ACID; T LYMPHOCYTE RECEPTOR GAMMA CHAIN; TARAZOTENE; TAZAROTENE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VACCINE;

ANAPHYLAXIS; BONE MARROW SUPPRESSION; BONE MARROW TRANSPLANTATION; CLINICAL TRIAL; FEVER; HUMAN; MYCOSIS FUNGOIDES; PANCREATITIS; PHOTOTHERAPY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PUVA; REVIEW; SEZARY SYNDROME; SKIN LYMPHOMA; STEM CELL TRANSPLANTATION; SURVIVAL; T CELL LYMPHOMA; TELANGIECTASIA;

EID: 0033966850     PISSN: 07338635     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0733-8635(05)70155-8     Document Type: Article

References (73)

1. Abel E.A. G.S. Wood R.T. Hoppe Mycosis fungoides: Clinical and histologic features, staging, evaluation, and approach to therapy CA Cancer J Clin 43 1993 93 113
2. J.R. Abrams M.G. Lebwohl C.A. Guzzo CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris J Clin Invest 103 1999 1243 1252
3. Asadullah K. Docke W.-D. A. HaeuBler Progression of Mycosis fungoides is associated with increasing cutaneous expression of interleukin-10 (IL-10) mRNA J Invest Dermatol 107 1996 833 837
4. K. Asadullah M. Friedrich W.D. Docke Enhanced expression of T-cell activation and natural killer cell antigens indicates systemic anti-tumor response in early primary cutaneous T-cell lymphoma J Invest Dermatol 108 1999 743 747
5. M. Baccard J.P. Marolleau M. Rybojad Middle-term evolution of patients with advanced cutaneous T-cell lymphoma treated with high-dose recombinant interleukin-2 Arch Dermatol 133 1997 656
6. C.L. Berger N. Wang I. Christensen The immune response to class I-associated tumor-specific cutaneous T-cell lymphoma antigens J Invest Dermatol 107 1996 392 397
7. R.D. Bigler P. Crilley B. Micaily Autologous bone marrow transplantation for advanced mycosis fungoides Bone Marrow Transplant 7 1991 133 137
8. J.J. Bright Z. Xin S. Sriram Superantigens augment antigen-specific Th1 responses by inducing IL-12 production in macrophages J Leukoc Biol 65 1999 5
9. P.A. Bunn S.J. Hoffman D. Norris Systemic therapy of cutaneous T-cell lymphomas (mycosis fungoides and the Sézary syndrome) Ann Intern Med 121 1994 592 602
10. D. Chakravarti V.J. LaMorte M.C. Nelson Role of CBP/P300 in nuclear receptor signalling Nature 383 1996 99 102
11. D.M. Chinn S. Chow Y.H. Kim Total skin electron beam therapy with or without adjuvant topical nitrogen mustard or nitrogen mustard alone as initial treatment of T2 and T3 mycosis fungoides Int J Radiat Oncol Biol Phys 43 1999 951 958
12. F.J. Cummings K. Kim R.S. Neiman Phase II trial of pentostatin in refractory lymphomas and cutaneous T-cell disease J Clin Oncol 9 1991 565 571
13. M. Duvic J.C. Cather J. Maize DAB389IL2 diptheria fusion toxin produces clinical responses in tumor stage cutaneous T-cell lymphoma Am J Hematol 58 1998 78 90
14. M. Duvic R.A.S. Chandraratna Retinoid receptor selectivity: Importance and clinical application in dermatology and other diseases Dermatologic Therapy 7 1998 7 14
15. M. Duvic N.A. Lemak J.R. Redman Combined modality therapy for cutaneous T-cell lymphoma J Amer Acad Dermatol 34 1996 1022 1029
16. Duvic M, Olsen E, Sams WM, et al: A phase III randomized double-blind placebo-controlled study of Peldesine (BCX-34) cream as topical therapy of cutaneous T-cell lymphoma. (in preparation)
17. R. Edelsen P. Helald M. Perez Photopheresis update Progress in Dermatology 25 1991 1 6
18. B. Escudier J.L. Lethiec E. Angevin Totally implanted catheters to reduce catheter-related infections in patients receiving interleukin-2: A 2-year experience Support Care Cancer 3 1995 297 300
19. F. Foss D. Breneman D. Ihde Phase II study of pentostatin and intermittent high-dose recombinant interferon alpha-2a in advanced mycosis fungoides/Sézary syndrome J Clin Oncol 10 1992 1907 1913
20. F.M. Foss D.C. Ihde I.R. Linnoila Phase II trial of fludarabine phosphate and interferon alpha-2a in advanced mycosis fungoides/Sézary syndrome J Clin Oncol 12 1994 2051 2059
21. F.M. Foss T.M. Kuzel Experimental therapies in the treatment of cutaneous T-cell lymphoma Hematol Oncol Clin North Am 95 1995 1127 1137
22. F.M. Foss E.A. Sausville Prognosis and staging of cutaneous T-cell lymphoma Hematol Oncol Clin North Am 9 1995 1011 1019
23. F.E. Fox M. Kubin M. Cassin Retinoids synergize with interleukin-2 to augment IFN-gamma and interleukin-12 production by human peripheral blood mononuclear cells J Interferon Cytokine Res 19 1999 407 415
24. F.E. Fox Z. Niu A. Tobia Photoactivated Hypericin is an anti-proliferative agent that induces a high rate of apoptotic death of normal, transformed, and malignant T lymphocytes: Implications for the treatment of cutaneous lymphoproliferative and inflammatory disorders J Invest Dermatol 111 1998 327 332
25. S.K. Ghosh J.T. Abrams H. Terunuma Human T-cell leukemia virus type I tax/rex DNA and RNA in cutaneous T-cell lymphoma Blood 84 1994 2663 2671
26. Heald P. Yan S.-L. R. Edelson Profound deficiency in normal circulating T-cells in erythrodermic cutaneous T-cell lymphoma Arch Dermatol 130 1994 198 203
27. H. Honigsmann Phototherapy and photochemotherapy Seminars in Dermatology 9 1990 84 89
28. R.T. Hoppe G.S. Wood E.A. Abel Mycosis fungoides and the Sézary syndrome: Pathology, staging, and treatment Curr Probl Cancer 14 1990 293 371
29. C.M. Jackow J.C. Cather V. Hearne Association of erythrodermic cutaneous T-cell lymphoma, superantigen-positive Staphylococcus aureus, and oligoclonal T-cell receptor Vb gene expansion Blood 89 1997 32 40
30. C.M. Jackow J.B. McHam A. Friss HLA-DR5 and DQB*03 class II alleles are associated with cutaneous T-cell lymphoma J Invest Dermatol 107 1996 373 376
31. D. Kaltoft B.H. Hansen K. Thestrup-Pedersen Cytogenetic findings in cell lines from cutaneous T-cell lymphoma Dermatology Clinics of North America 12 1994 295 304
32. L. Karenko E. Hyytinen S. Sarna Chromosomal abnormalities in cutaneous T-cell lymphoma and in its premalignant conditions as detected by G-banding and interphase cytogenetic methods J Invest Dermatol 108 1997 22 29
33. Y.H. Kim K. Bishop A. Varghese Prognostic factors in erythrodermic mycosis fungoides and the Sézary syndrome Arch Dermatol 131 1995 1003 1008
34. Y.H. Kim S. Chow A. Varghese Clinical characteristics and long-term outcome of patients with generalized patch or plaque (T2) mycosis fungoides Arch Dermatol 135 1999 26 32
35. M. Koeppel A. Stoppa M. Resbeut Mycosis fungoides and allogenic bone marrow transplantation Acta Derm Venereol (Stockh) 74 1994 331 332
36. D.H. Kono R. Baccala R.S. Balderas Application of a multiprobe RNase protection assay and junctional sequences to define Vb gene diversity in Sézary syndrome Am J Pathol 140 1992 823 830
37. J.G. Krueger J.T. Wolfe R.T. Nabeya Successful ultraviolet B treatment of psoriasis is accompanied by a reversal of keratinocyte pathology and by selective depletion of intraepidermal T cells J Exp Med 182 1995 2057 2068
38. T.M. Kuzel H.H. Roenigk E. Samuelson Effectiveness of interferon alfa-2a combined with phototherapy for mycosis fungoides and the Sézary syndrome J Clin Oncol 13 1995 257 263
39. C.F. LeMaistre M.N. Saleh T.M. Kuzel Phase I trial of a ligand fusion protein (DAB389IL-2) in lymphomas expressing the receptor for interleukin-2 Blood 91 1998 399 405
40. G. Li B.R. Vowels B.M. Benoit Failure to detect human T-lymphotropic virus type (HTLV-1) proviral DNA in cell lines and tissues from patients with cutaneous-cell lymphoma J Invest Dermatol 107 1996 308 313
41. J. Limon B. Nedoszytko I. Brozek Chromosome aberrations, spontaneous SCE, and growth kinetics in PHA-stimulated lymphocytes of five cases with Sézary syndrome Cancer Genet Cytogenet 83 1995 75 81
42. G. Lisby M.S. Reitz G.L. Vejlsgaard No detection of HTLV-I DNA in punch skin biopsies from patients with cutaneous T-cell lymphomas by polymerase chain reaction J Invest Dermatol 98 1992 417 420
43. J. Longley L. Tyrrell S.Z. Lu Malignant and normal T cells show random use of T-cell receptor alpha chain variable regions in patients with cutaneous T cell lymphoma J Invest Dermatol 105 1995 62 64
44. J.P. Marolleau M. Baccard B. Flageul High-dose recombinant interleukin-2 in advanced cutaneous T-cell lymphoma Arch Dermatol 131 1995 574 579
45. J.M. McGregor T. Crook B. Ng p53 gene mutations in cutaneous T-cell lymphoma J Invest Dermatol 106 1996 855
46. C. Miracco P. Rubegni De Aloe G. Extracorporeal photochemotherapy induces apoptosis of infiltrating lymphoid cells in patients with mycosis fungoides in early stages. A quantitative histological study Br J Dermatol 137 1997 549 557
47. R.L. Modlin Th1-Th2 paradigm: Insights from leprosy J Invest Dermatol 102 1994 828 832
48. J. Muche A. Lukowsky K. Asadullah Demonstration of frequent occurrence of clonal T-cells in the peripheral blood of patients with primary cutaneous T-cell lymphoma Blood 90 1997 1636 1642
49. J. Nichols F. Foss T.M. Kuzel Interleukin-2 fusion protein: An investigational therapy for interleukin-2 receptor expressing malignancies Eur J Cancer 33 1997 S34 S36
50. S. O'Brien R. Kurzrock M. Duvic 2-chlorodeoxyadenosine therapy in patients with T-cell lymphoproliferative disorders Blood 84 1994 733 738
51. Olsen EA, Duvic M, Frankel A, et al: Pivotal Phase III trial of two dose levels of DAB-IL2 (Ontak) for the treatment of cutaneous T-cell lymphoma. J Clin Oncol (in press)
52. B.A. Pancake D. Zucker-Franklin E.E. Coutavas The cutaneous T-cell lymphoma, mycosis fungoides, is a human T-cell lymphotrophic virus-associated disease J Clin Invest 95 1995 547 554
53. D.L. Ramsay J.A. Meller H.S. Zackheim Topical treatment of early cutaneous T-cell lymphoma Hematol Oncol Clin North Am 9 1995 1031 1056
54. A.H. Rook G.S. Wood E.K. Yoo Interleukin-12 therapy of cutaneous T-cell lymphoma induces lesion regression and cytotoxic T-cell responses Blood 94 1999 902 908
55. Saleh M.N. Le Maistre C.F. T.M. Kuzel Antitumor activity of DAB389-IL-2 fusion toxin in mycosis fungoides J Am Acad Dermatol 39 1998 63 73
56. A. Sarris D. Daliani R. Ulner Interferon-inducible Protein 10 as possible factor in the pathogenesis of cutaneous T-cell lymphoma Clinical Cancer Research 3 1997 169 177
57. S.I. Sherman J. Gopal B.R. Haugen Central hypothyroidism associated with retinoid X receptor-selective ligands N Engl J Med 340 1999 1075 1079
58. A.A. Sinha P. Heald Advances in the management of cutaneous T-cell lymphoma Dermatol Clin 16 1998 301 311
59. J.C. Sterling R. Marcus N.P. Burrows Erythyrodermic mycosis fungoides treated with total body irradiation and autologous bone marrow transplantation Clinical and Experimental Dermatology 20 1995 73 75
60. R.S. Stern T.N. Khanh Vakeva L.H. PUVA follow-up study Malignant melanoma in patients treated for psoriasis with methoxalen (psoralen) and UVA radiation (PUVA) N Engl J Med 336 1997 1041 1045
61. K. Svanberg T. Andersson D. Killander Photodynamic therapy of nonmelanoma malignant tumours of the skin using topical delta-amino levulinic acid sensitization and laser irradiation Br J Dermatol 130 1994 743 751
62. R.S.H. Tan C.M. Butterworth H. McLaughlin Mycosis fungoides–a disease of antigen persistence Br J Dermatol 91 1974 607 616
63. A. Tanew S. Radakovic-Fijan M. Schemper Narrowband UV-B phototherapy vs photochemotherapy in the treatment of chronic plaque-type psoriasis: A paired comparison study Arch Dermatol 135 1999 519 524
64. Von Hoff D.D. S. Dahlberg R.J. Hartsock Activity of fludarabine monophosphate in patients with advanced mycosis fungoides: A Southwest Oncology Group Study J Natl Cancer Inst 82 1990 1353 1355
65. B.R. Vowels M. Cassin E.C. Vonderheid Aberrant cytokine production by Sézary syndrome patients: Cytokine secretion pattern resembles murine TH2 cells J Invest Dermatol 99 1992 90 94
66. M.A. Weinstock J.W. Horn Mycosis fungoides in the United States: Increasing incidence and description JAMA 260 1988 42 46
67. M. Weinstock J.F. Reynes The changing survival of patients with mycosis fungoides: A population-based assessment of trends in the United States Cancer 85 1999 208 212
68. L.D. Wilson A.L. Licata I.M. Braverman Systemic chemotherapy and extracorporeal photochemotherapy for T3 and T4 cutaneous T-cell lymphoma patients who have achieved a complete response to total skin electron beam therapy Int J Radiat Oncol Biol Phys 32 1995 987 995
69. G.S. Wood A. Edinger R.T. Hoppe Mycosis fungoides skin lesions contain CD8+ tumor-infiltrating lymphocytes expressing an activated, MHC-restricted cytotoxic T lymphocyte phenotype J Cutan Pathol 21 1994 151 156
70. G.S. Wood J.M. Schaffer R. Boni No evidence of HTLV proviral integration in lymphoproliferative disorders associated with cutaneous T-cell lymphoma J Invest Dermatol 106 1996 914
71. H.S. Zackheim Treatment of cutaneous T cell lymphoma with retinoids Dermatologic Therapy 7 1998 15 20
72. H.S. Zackheim E.H. Epstein Treatment of mycosis fungoides with topical nitrosourea compounds: Further studies Arch Dermatol 111 1975 1564 1570
73. A. Ziegler D.F. Leffel S. Kunala Mutation hotspots due to sunlight in the p53 gene of non-melanoma skin cancer PNAS 90 1993 4216 4220